About
Dr. Mark Yarchoan is an Associate Professor of Oncology at the Johns Hopkins University School of Medicine and a physician-scientist specializing in liver cancer, cancer immunotherapy, and therapeutic cancer vaccines. His clinical and research interests focus on hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and fibrolamellar carcinoma (FLC). Dr. Yarchoan leads an NIH-funded translational research laboratory focused on understanding mechanisms of response, resistance, and toxicity associated with immunotherapy in solid tumors, as well as developing novel immunotherapies. His early research contributed to establishing the association between tumor mutational burden (TMB),...